

Norgen Biotek Launches Another Novel Firstof-Its-Kind Kit for Bacterial Extracellular Vesicles Isolation

Empowering researchers to bridge gap in extracellular vesicle research and discovery.

TOKYO, JAPAN, October 28, 2025 /EINPresswire.com/ -- Norgen Biotek Corp., a leading Canadian biotechnology company specializing in molecular diagnostics nucleic acid and



exosome stabilization purification technologies, is proud to announce the commercial launch of its <u>Bacterial EV Isolation Kit</u>. The first product on the market specifically designed to isolate extracellular vesicles from bacterial samples.



Our leadership in EV-based solutions has enabled us to develop this novel kit, and we are confident it will become a critical resource for researchers."

Dr. Yousef Haj-Ahmad, President and CEO of Norgen Biotek This advancement expands the capabilities of extracellular vesicle (EV) research, unlocking new potential for microbiome studies, host-pathogen interactions, and therapeutic development. As the first commercially available solution for bacterial exosome isolation, Norgen continues to set the standard in the EV space.

"We are excited to pioneer a tool that opens the door to a previously inaccessible area of research," said Dr. Yousef Haj-Ahmad, President and CEO of Norgen Biotek. "Our leadership in EV-based solutions has enabled us to

develop this novel kit, and we are confident it will become a critical resource for researchers."

Norgen already offers a range of kits to isolate extracellular vesicles from bodily fluids, including urine, blood, and saliva. Now, we're introducing a new kit for bacterial extracellular vesicles, powered by our patented silicon carbide (SiC) resin, a technology that has already transformed exosome purification workflows across the board. Norgen remains the leader in the EV market, with a scalable product line that continues to expand possibilities in precision medicine research.

About Norgen Biotek Corp.

Norgen Biotek is a privately-held
Canadian biotech company committed
to providing innovative products and
services to the life sciences and
pharmaceutical industry. Norgen has
developed technologies and products
for the purification of nucleic acids and
proteins on both preparative and
industrial scales, including ready-to-use
chromatography resins and pre-packed
chromatography columns. Detailed
information about the company is
available at www.norgenbiotek.com.



For further information, please contact:

Dr. Yousef Haj-Ahmad, President & CEO Norgen Biotek Corp.

+1 905-227-8848

email us here

Visit us on social media:

LinkedIn

Bluesky

Instagram

Facebook

YouTube

TikTok

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/860200207

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.